Ocuphire Pharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to researching and bringing to market treatments for various refractive and retinal eye conditions. The company's primary investigational drug is Nyxol eye drops, a preservative-free phentolamine mesylate formulation administered once daily. Nyxol is currently undergoing advanced (Phase III) clinical trials for individuals experiencing difficulties with dim light or night vision.